CRB Signs Exclusive Japanese Distribution Deal with BioBridge
News Mar 30, 2012
Cambridge Research Biochemicals (CRB) has announced that it will be expanding its business into Asia through the signing of an exclusive deal with BioBridge. BioBridge will be responsible for the sales and marketing of CRB’s products in Japan.
This agreement is one of a series that has seen CRB continuing to grow through the wider economic difficulties of the last two years by increasing market share in existing territories and penetrating new overseas markets within Europe, North America and now Asia.
The company is hoping to continue its expansion programme into other Asian markets through similar types of exclusive partnerships.
Emily Humphrys, Commercial Director added “We are delighted to appoint BioBridge as our Japanese agent as it allows us to expand more rapidly into Japan and we envisage Japanese clients will appreciate CRB's high quality products: peptides and antibodies and the client focused customer service we provide. BioBridge were highly recommended to us by Quotient Bioresearch: a strategic partner to CRB for radiolabelled peptides who already partner with BioBridge and has built up a good presence in Japan.”
Yoshiyuki, Director of BioBridge K.K. confirms the benefits of the signing of this deal for the Japanese life science supply chain market, “BioBridge plays a key role as a sales and marketing bridge between these European companies and the Japanese pharmaceutical and life science industry. We recognize that CRB has built up an excellent reputation in the international peptides and antibodies supply chain by working closely with their customers to offer them products that are reflective of their needs, rather than taking an “off-the-shelf” approach. This approach is extremely important for the Japanese pharmaceutical market that has differing needs to their counterparts in other parts of the world. We are looking forward to being able to offer this type of service with CRB’s products to our existing and new customers.”
CRB custom services that will now be available to the Japanese market include:
• Peptides Synthesis
• Polyclonal Antibody Production
• Monoclonal Antibody Production
• Fluorescent Dyes Labelling
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE